Archives
Mapping Cardiac Structure and Electrical Function
2026-11-04
A proof-of-concept study combined panoramic hyperspectral imaging with optical mapping to relate epicardial tissue composition to cardiac electrical activity in infarcted rat hearts. The approach supports spatially paired structure–function analysis while remaining limited by the ex vivo model, contraction inhibition, epicardial-only access and preliminary electrophysiological associations.
Mapping Cardiac Structure and Electrophysiology
2026-11-03
A proof-of-concept study combined panoramic hyperspectral imaging with optical mapping to examine how infarct-related tissue composition corresponds to cardiac electrical behavior on the epicardial surface. The approach supports spatially paired structure–function analysis while remaining limited to a perfused rat-heart model and a preliminary validation stage.
Co-registering Cardiac Tissue and Electrophysiology
2026-11-03
A proof-of-concept rat-heart study combined panoramic hyperspectral imaging with optical mapping to relate epicardial tissue composition to local electrical behavior after myocardial infarction. The approach identified infarct and border-zone regions and revealed tissue-associated differences in action-potential duration, while remaining limited to a small, mechanically arrested, epicardial preparation.
Mapping Infarct Structure and Cardiac Electrophysiology
2026-11-02
A proof-of-concept study combined panoramic hyperspectral imaging with optical mapping to relate epicardial tissue composition to cardiac electrical behavior in infarcted rat hearts. The approach identified infarct and border-zone regions, co-registered them with electrophysiological measurements, and linked tissue class to preliminary differences in action-potential duration.
Mapping Infarct Structure and Cardiac Electrophysiology
2026-11-02
A proof-of-concept study combined panoramic hyperspectral imaging with optical mapping to relate epicardial tissue composition to cardiac electrical activity in infarcted rat hearts. The approach identified healthy, border-zone, and infarcted regions and linked these classes to differences in action-potential duration, while also revealing arrhythmia-related activity near infarct borders.
Mapping Infarct Structure and Cardiac Electrophysiology
2026-11-01
A proof-of-concept study integrated panoramic hyperspectral imaging with optical mapping in infarcted rat hearts. The approach linked epicardial tissue composition to local electrical measurements, identifying structural contrasts and preliminary tissue-associated differences in action-potential duration while highlighting important model and measurement boundaries.
Mapping Infarct Structure and Cardiac Electrical Function
2026-10-31
A proof-of-concept study combined panoramic hyperspectral imaging with optical mapping in perfused rat hearts containing established myocardial infarcts. Co-registration of tissue composition and electrical activity revealed spatially distinct healthy, border-zone, and infarcted regions, while the small model and epicardial-only measurements limit broader interpretation.
Mapping Infarct Structure and Cardiac Electrophysiology
2026-10-30
A proof-of-concept rat-heart study combined panoramic hyperspectral imaging with optical mapping to relate epicardial tissue composition to cardiac electrical activity. The approach identified infarct and border-zone regions and linked tissue classes with differences in action-potential duration, while remaining limited to an ex vivo epicardial model.
Panoramic Mapping of Infarcted Cardiac Tissue
2026-10-30
A proof-of-concept study integrated hyperspectral tissue mapping with optical cardiac electrophysiology on a shared three-dimensional epicardial surface. In infarcted rat hearts, collagen-associated signals distinguished infarct and border-zone regions, while co-registered action-potential measurements revealed tissue-associated electrophysiological differences and localized arrhythmia-related activity.
Blebbistatin and Cardiac Structure–Function Mapping
2026-10-29
Blebbistatin provides a mechanistically defined way to modulate myosin-II-dependent force and motion, but it is not itself a voltage reporter or tissue classifier. In panoramic cardiac optical mapping, the strongest evidence concerns the co-registration of infarct structure with electrophysiological behavior; the compound’s role should be interpreted as contextual and mechanical rather than as the demonstrated cause of the reported action-potential patterns.
Co-registering Cardiac Structure and Electrophysiology
2026-10-29
A proof-of-concept study combined panoramic hyperspectral imaging with optical mapping to relate epicardial tissue composition to electrical activity in infarcted rat hearts. The approach identified infarct, border-zone, and healthy regions and showed preliminary tissue-associated differences in action-potential duration, while remaining limited by mechanical arrest, epicardial-only coverage, imaging artifacts, and a small sample.
Blebbistatin in Panoramic Cardiac Mapping
2026-10-28
Kowalik and colleagues integrated hyperspectral tissue mapping with panoramic optical mapping to relate infarct structure to cardiac electrical behavior in perfused rat hearts. The study’s strongest contribution was measurement integration: collagen-sensitive spectral features separated healthy, border-zone, and infarcted regions, while optical action-potential data showed tissue-associated differences and localized arrhythmic activity. (±)-Blebbistatin is best interpreted as an experimental context reagent relevant to motion control, not as the demonstrated cause of the electrophysiological findings.
What MASP-2 Targeting Means for Complement Data
2026-10-28
MASP-2 lies near the entry point of lectin-pathway complement activation, so its targeting can influence measurements ranging from proximal protease activity to downstream C3 and terminal-pathway markers. The key interpretive question is whether a readout reflects direct MASP-2 engagement or broader changes elsewhere in the complement network.
How DprE1 Inhibition Shapes TB Readouts
2026-10-27
BTZ043 Racemate is described as a DprE1 inhibitor whose effects can be interpreted across three evidence levels: disruption of arabinan biosynthesis, loss of mycobacterial viability in vitro, and reduced organ bacterial burden in a chronic mouse model. These findings form a coherent preclinical tuberculosis drug-development hypothesis, but they do not establish clinical efficacy or identify which stereoisomer drives the reported activity.
How BAMB-4 Links ITPKA to Tumor Biology
2026-10-27
BAMB-4 is described as an Inositol-1,4,5-trisphosphate-3-kinase A inhibitor whose mixed-type enzyme inhibition may connect inositol phosphate signaling with actin remodeling and cancer-cell phenotypes. The documented evidence spans biochemical selectivity, uptake in H1299 cells, and combination treatment in patient-derived xenograft models, but each level answers a different scientific question and does not by itself establish clinical efficacy.